ISA Pharmaceuticals long term study confirms efficacy of our T-cell activating immunotherapy in combination with checkpoint inhibitor
- Data published in the Journal of ImmunoTherapy of Cancer confirms efficacy of combination treatment (ISA101b + anti-PD1)
- Deep and durable responses have a profound positive effect on patient prognosis with patients disease-free for more than 44 months
- Improved tumour infiltration by immune cells predicted response to therapy
Oegstgeest, March 1, 2022 – ISA today announces the publication of extension data from a key study using lead product ISA101b in the Journal of ImmunoTherapy of Cancer. The study, ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response, is performed by Guimaraes Sousa, Michael Curran, Bonnie Glisson et al. in collaboration with the MD Anderson Cancer Center in Houston, Texas.
